NASDAQ: VRNAVerona Pharma PLC Stock
$15.31+0.07 (+0.46%)
Updated Apr 25, 2024
VRNA Price
$15.31
Fair Value Price
$3.47
Market Cap
$1.24B
52 Week Low
$11.83
52 Week High
$23.81
P/E
-21.26x
P/B
4.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$54.37M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$50M
Beta
1.05
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VRNA Overview
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRNA ($15.31) is overvalued by 341.67% relative to our estimate of its Fair Value price of $3.47 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRNA ($15.31) is not significantly undervalued (341.67%) relative to our estimate of its Fair Value price of $3.47 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRNA due diligence checks available for Premium users.
Be the first to know about important VRNA news, forecast changes, insider trades & much more!
VRNA News
Valuation
VRNA fair value
Fair Value of VRNA stock based on Discounted Cash Flow (DCF)
Price
$15.31
Fair Value
$3.47
Overvalued by
341.67%
VRNA ($15.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRNA ($15.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.26x
Industry
15.41x
Market
40.97x
VRNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.96x
Industry
5.8x
VRNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.1M
Profit Margin
0%
VRNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$308.1M
Liabilities
$58.8M
Debt to equity
0.24
VRNA's short-term assets ($289.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRNA's short-term assets ($289.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VRNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
$0.0
Financing
$24.0M
VRNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRNA vs Biotech Stocks
Verona Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.